🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

United Therapeutics Corporation (UTHR)

NASDAQ
Currency in USD
410.00
+7.43(+1.85%)
Closed
After Hours
409.47-0.53(-0.13%)
UTHR Scorecard
Full Analysis
Management has been aggressively buying back shares
Trading near 52-week High
Fair Value
Day's Range
403.35417.82
52 wk Range
208.62417.82
Prev. Close
402.57
Open
403.35
Day's Range
403.35-417.82
52 wk Range
208.62-417.82
Volume
498,743
Average Volume (3m)
396,191
1-Year Change
84.92%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
UTHR Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
382.29
Downside
-6.76%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet
Show more

United Therapeutics Corporation Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Compare UTHR to Peers and Sector

Metrics to compare
UTHR
Peers
Sector
Relationship
P/E Ratio
16.5x−2.9x−0.6x
PEG Ratio
0.64−0.050.00
Price/Book
3.0x2.8x2.6x
Price / LTM Sales
6.6x1.7x3.2x
Upside (Analyst Target)
−6.0%57.5%44.1%
Fair Value Upside
Unlock11.0%6.2%Unlock

People Also Watch

53.82
PPC
+2.81%
86.28
FIVE
-5.73%
124.01
NTAP
+0.96%
259.47
HEI
+2.51%
19.26
ACI
-0.41%

FAQ

What Is the United Therapeutics (UTHR) Stock Price Today?

The United Therapeutics stock price today is 410.00

What Stock Exchange Does United Therapeutics Trade On?

United Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for United Therapeutics?

The stock symbol for United Therapeutics is "UTHR."

What Is the United Therapeutics Market Cap?

As of today, United Therapeutics market cap is 18.30B.

What is United Therapeutics Earnings Per Share?

The United Therapeutics EPS is 24.28.

What Is the Next United Therapeutics Earnings Date?

United Therapeutics will release its next earnings report on 18 Feb 2025.

From a Technical Analysis Perspective, Is UTHR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.